BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 23263341)

  • 1. Predictive value of the model for end-stage liver disease score in patients undergoing left ventricular assist device implantation.
    Deo SV; Daly RC; Altarabsheh SE; Hasin T; Zhao Y; Shah IK; Stulak JM; Boilson BA; Schirger JA; Joyce LD; Park SJ
    ASAIO J; 2013; 59(1):57-62. PubMed ID: 23263341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Model of End-Stage Liver Disease-eXcluding International Normalized Ratio (MELD-XI) Scoring System to Predict Outcomes in Patients Who Undergo Left Ventricular Assist Device Implantation.
    Critsinelis A; Kurihara C; Volkovicher N; Kawabori M; Sugiura T; Manon M; Wang S; Civitello AB; Morgan JA
    Ann Thorac Surg; 2018 Aug; 106(2):513-519. PubMed ID: 29626453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model for end-stage liver disease score predicts adverse events related to ventricular assist device therapy.
    Bonde P; Ku NC; Genovese EA; Bermudez CA; Bhama JK; Ciarleglio MM; Cong X; Teuteberg JJ; Kormos RL
    Ann Thorac Surg; 2012 May; 93(5):1541-7; discussion 1547-8. PubMed ID: 22480391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MELD-XI score and cardiac mortality or transplantation in patients after Fontan surgery.
    Assenza GE; Graham DA; Landzberg MJ; Valente AM; Singh MN; Bashir A; Fernandes S; Mortele KJ; Ukomadu C; Volpe M; Wu F
    Heart; 2013 Apr; 99(7):491-6. PubMed ID: 23406689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous-flow left ventricular assist device therapy in patients with preoperative hepatic failure: are we pushing the limits too far?
    Weymann A; Patil NP; Sabashnikov A; Mohite PN; Garcia Saez D; Bireta C; Wahlers T; Karck M; Kallenbach K; Ruhparwar A; Fatullayev J; Amrani M; De Robertis F; Bahrami T; Popov AF; Simon AR
    Artif Organs; 2015 Apr; 39(4):336-42. PubMed ID: 25345547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in renal function after implantation of continuous-flow left ventricular assist devices.
    Hasin T; Topilsky Y; Schirger JA; Li Z; Zhao Y; Boilson BA; Clavell AL; Rodeheffer RJ; Frantz RP; Edwards BS; Pereira NL; Joyce L; Daly R; Park SJ; Kushwaha SS
    J Am Coll Cardiol; 2012 Jan; 59(1):26-36. PubMed ID: 22192665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The aspartate transaminase/alanine transaminase (DeRitis) ratio predicts mid-term mortality and renal and respiratory dysfunction after left ventricular assist device implantation.
    Pilarczyk K; Carstens H; Heckmann J; Canbay A; Koch A; Pizanis N; Jakob H; Kamler M
    Eur J Cardiothorac Surg; 2017 Oct; 52(4):781-788. PubMed ID: 29156019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of pre-operative interleukin-6 levels with Interagency Registry for Mechanically Assisted Circulatory Support profiles and intensive care unit stay in left ventricular assist device patients.
    Caruso R; Verde A; Cabiati M; Milazzo F; Boroni C; Del Ry S; Parolini M; Vittori C; Paino R; Martinelli L; Giannessi D; Frigerio M; Parodi O
    J Heart Lung Transplant; 2012 Jun; 31(6):625-33. PubMed ID: 22386451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-cardiac transplant survival after support with a continuous-flow left ventricular assist device: impact of duration of left ventricular assist device support and other variables.
    John R; Pagani FD; Naka Y; Boyle A; Conte JV; Russell SD; Klodell CT; Milano CA; Rogers J; Farrar DJ; Frazier OH
    J Thorac Cardiovasc Surg; 2010 Jul; 140(1):174-81. PubMed ID: 20447659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver dysfunction as a predictor of outcomes in patients with advanced heart failure requiring ventricular assist device support: Use of the Model of End-stage Liver Disease (MELD) and MELD eXcluding INR (MELD-XI) scoring system.
    Yang JA; Kato TS; Shulman BP; Takayama H; Farr M; Jorde UP; Mancini DM; Naka Y; Schulze PC
    J Heart Lung Transplant; 2012 Jun; 31(6):601-10. PubMed ID: 22458997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection.
    Lietz K; Long JW; Kfoury AG; Slaughter MS; Silver MA; Milano CA; Rogers JG; Naka Y; Mancini D; Miller LW
    Circulation; 2007 Jul; 116(5):497-505. PubMed ID: 17638928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extracorporeal membrane oxygenation as perioperative right ventricular support in patients with biventricular failure undergoing left ventricular assist device implantation.
    Scherer M; Sirat AS; Moritz A; Martens S
    Eur J Cardiothorac Surg; 2011 Jun; 39(6):939-44; discussion 944. PubMed ID: 21071240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative atrial fibrillation increases risk of thromboembolic events after left ventricular assist device implantation.
    Stulak JM; Deo S; Schirger J; Aaronson KD; Park SJ; Joyce LD; Daly RC; Pagani FD
    Ann Thorac Surg; 2013 Dec; 96(6):2161-7. PubMed ID: 24035302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of age on outcomes following continuous-flow left ventricular assist device implantation.
    Lushaj EB; Badami A; Osaki S; Murray M; Leverson G; Lozonschi L; Akhter S; Kohmoto T
    Interact Cardiovasc Thorac Surg; 2015 Jun; 20(6):743-8. PubMed ID: 25770085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural history and clinical effect of aortic valve regurgitation after left ventricular assist device implantation.
    Rajagopal K; Daneshmand MA; Patel CB; Ganapathi AM; Schechter MA; Rogers JG; Milano CA
    J Thorac Cardiovasc Surg; 2013 May; 145(5):1373-9. PubMed ID: 23312101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive Value of Models for End-Stage Liver Disease Score in Patients With Pulsatile Flow POLVAD MEV Left Ventricular Assist Device Support.
    Nadziakiewicz P; Szyguła-Jurkiewicz B; Pacholewicz J; Zakliczyński M; Przybyłowski P; Krauchuk A; Łowicka M; Zembala M
    Transplant Proc; 2018 Sep; 50(7):2075-2079. PubMed ID: 30177112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative Pectoralis Muscle Quantity and Attenuation by Computed Tomography Are Novel and Powerful Predictors of Mortality After Left Ventricular Assist Device Implantation.
    Teigen LM; John R; Kuchnia AJ; Nagel EM; Earthman CP; Kealhofer J; Martin C; Cogswell R
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28912261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Model for End-stage Liver Disease score fails to predict perioperative outcome after hepatic resection for hepatocellular carcinoma in patients without cirrhosis.
    Teh SH; Sheppard BC; Schwartz J; Orloff SL
    Am J Surg; 2008 May; 195(5):697-701. PubMed ID: 18367132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low incidence of bleeding-related morbidity with left ventricular assist device implantation in the current era.
    Krishan K; Nair A; Pinney S; Adams D; Anyanwu AC
    Artif Organs; 2012 Aug; 36(8):746-51. PubMed ID: 22607225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative liver dysfunction influences blood product administration and alterations in circulating haemostatic markers following ventricular assist device implantation.
    Woolley JR; Kormos RL; Teuteberg JJ; Bermudez CA; Bhama JK; Lockard KL; Kunz NM; Wagner WR
    Eur J Cardiothorac Surg; 2015 Mar; 47(3):497-504. PubMed ID: 24810756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.